FibroBiologics pipeline update: CYWC628 pre-clinical data shows improved wound healing vs Grafix

FibroBiologics, Inc.

CYWC628 multiple administration study: 69.3% wound area reduction at day 12 vs 47.13% for Grafix (p<0.05).
Planning Phase 1/2 clinical trial in Australia for diabetic foot ulcers in 2025, results expected Q3 2025.
FDA IND clearance for CybroCell Phase 1/2 trial for degenerative disc disease, conditional on master cell bank.
Expect to complete remaining CYWC628 pre-clinical studies (toxicity, dose titration) in Q3 2024.
Manufacturing: planning CDMO transfer; master cell bank, working cell bank, and drug product by end of 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.